ARTICLE | Company News
Neurocrine, GlaxoSmithKline in neurological deal
July 24, 2001 7:00 AM UTC
NBIX and GlaxoSmithKline (GSK; LSE:GSK) will develop and market corticotropin releasing factor receptor (CRF-R1 and CRF-R2) antagonists for psychiatric, neurological and gastrointestinal diseases. The...